1 Division of Biomedical Sciences, Imperial College School of Medicine, Charing Cross Hospital, London W6 8RF; and 2 Centre for Nephrology, Royal Free and University College Medical School, London W1N 8AA, United Kingdom
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To test the proposal that
the enzyme 11-hydroxysteroid dehydrogenase (11
-HSD) confers
aldosterone specificity on mineralocorticoid receptors in the distal
nephron by inactivating glucocorticoids, we performed a free-flow
micropuncture study of distal tubular function in adrenalectomized rats
infused with high-dose corticosterone. One-half of the rats were
additionally given intravenous carbenoxolone (CBX; 6 mg/h) to inhibit
renal 11
-HSD activity. Although this maneuver lowered fractional
Na+ excretion (1.1 ± 0.2 vs. 1.9 ± 0.2%,
P < 0.01), Na+ reabsorption within the
accessible distal tubule was found to be similar in the two groups of
animals. In contrast, distal tubular K+ secretion was
enhanced in CBX-treated rats: fractional K+ deliveries to
the early and late distal collection sites in the corticosterone-alone
group were 13 ± 1 and 20 ± 3%, respectively (not
significant), whereas corresponding data in the CBX-treated group were
9 ± 1 and 24 ± 2% (P < 0.01). This
stimulation of distal K+ secretion provides the first
direct in vivo evidence that 11
-HSD normally prevents corticosterone
from exerting a mineralocorticoid-like effect in the distal tubule. The
reduction in fractional Na+ excretion during inhibition of
11
-HSD, in the absence of a change in end-distal Na+
delivery, suggests enhanced Na+ reabsorption in the
collecting ducts.
carbenoxolone; sodium reabsorption; potassium secretion; micropuncture; corticosterone
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
IN VITRO STUDIES
HAVE DEMONSTRATED that mineralocorticoid receptors (MR) have
equal affinity for aldosterone and glucocorticoids (26),
yet in vivo they display specificity for aldosterone in the face of
much higher circulating concentrations of glucocorticoids. It has been
proposed that this specificity is conferred by the type 2 isoform of
11-hydroxysteroid dehydrogenase (11
-HSD), an enzyme that converts
glucocorticoids (cortisol in humans, corticosterone in rodents) to
inactive 11-ketosteroid derivatives and is found in
mineralocorticoid-sensitive tissues including the distal nephron (4, 8, 11).
This hypothesis has received considerable support from in vitro
experiments (3, 11, 20) and from the observation that individuals with mutations of the gene encoding 11-HSD2 display the
syndrome of apparent mineralocorticoid excess, a condition characterized by Na+ retention, hypertension, and
hypokalemia in the absence of elevated aldosterone levels (33,
40); it has also been demonstrated that mice with targeted
disruption of the 11
-HSD2 gene are hypokalemic and hypertensive
(16). To date, however, no direct in vivo confirmation of
the proposed role for 11
-HSD in the distal nephron has been provided.
11-HSD can be inhibited in vitro by glycyrrhetinic acid, which is
the active constituent of licorice, or by its hemisuccinate derivative
carbenoxolone (CBX) (8, 11, 20). In a recent clearance
study, we infused CBX into intact, anesthetized rats and confirmed
dose-dependent inhibition of renal 11
-HSD, measured directly ex vivo
(25). We were able to demonstrate a fall in Na+ excretion, in the absence of a change in glomerular
filtration rate, when renal 11
-HSD activity was inhibited by
>90%. However, because clearance studies are unable to
provide precise localization of tubular effects, the site of the
enhanced Na+ reabsorption could not be identified.
Furthermore, because the animals had intact adrenals, possible
confounding influences of altered endogenous adrenocorticosteroid
secretion could not be discounted.
In the present study, to test directly the proposed role of 11-HSD
in the distal nephron, we have used in vivo micropuncture to
investigate distal tubular function during CBX infusion in adrenalectomized, hormone-replaced rats. It was reasoned that, if the
hypothesis were correct, inhibition of 11
-HSD should prevent inactivation of infused glucocorticoid and thereby allow it to gain
access to MR, leading to mineralocorticoid-like effects (increased Na+ reabsorption, increased K+ secretion) in
the distal tubule.
![]() |
METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Adrenalectomy
Adult male Sprague-Dawley rats weighing 220-240 g were adrenalectomized via bilateral flank incisions under halothane anesthesia (Fluothane, ICI, Macclesfield, Cheshire, UK). At the same time, a 14-day osmotic minipump (Alzet, model 2002, Alza, Palo Alto, CA) was implanted subcutaneously on the back of the neck of each animal. The pump contained a solution of D-aldosterone and dexamethasone (both from Sigma, Poole, Dorset, UK) dissolved in polyethylene glycol 400 (Sigma) so as to deliver basal levels of aldosterone (5 µg · kg body wtAfter adrenalectomy and minipump implantation, rats had free access to water and a standard rat diet containing 140 mmol Na+ and 180 mmol K+/kg dry wt. In addition, 2.7% (0.46 M) saline was provided as a drinking option up to the time of micropuncture experiments. Adrenalectomized animals drank 5.2 ± 0.5 (SE) ml/day of the hypertonic saline, whereas when it was offered as an option to adrenal-intact rats, negligible quantities were drunk. Rats were weighed immediately before surgery, 24 h after surgery, and then every day thereafter at the same time, to monitor weight gain.
Micropuncture Studies
Experiments were conducted 6-8 days postadrenalectomy, by which time the rats had gained 20-40 g compared with their preoperative weight. On the day of study, rats were anesthetized with Intraval (110 mg/kg ip, May & Baker, Dagenham, UK) and prepared surgically for micropuncture experiments (28). Rectal temperature was maintained at 37°C, a tracheotomy was performed, and the bladder was catheterized. The right femoral artery was cannulated for blood pressure monitoring and blood sampling. The left kidney was exposed by a subcostal incision, freed from perirenal fat, and immobilized in a Perspex dish rigidly attached to the operating table. The kidney surface was bathed with paraffin oil heated to 37°C. The left ureter was cannulated close to the pelvis. A total of four polyethylene intravenous cannulas were used: two were placed in the right jugular vein, one in the left jugular vein, and one in the right femoral vein. The left jugular vein cannula was used for Lissamine green injection, while the other three were for infusions as described below.Control group (corticosterone alone; n = 12 rats). Corticosterone (Sigma), dissolved in isotonic saline containing 1.5% ethanol, was infused through one of the jugular cannulas (60 µg/ml, 4 ml/h) to administer corticosterone at 240 µg/h. Isotonic saline was infused at 1 ml/h through the right femoral cannula, making a total fluid infusion rate of 5 ml/h.
One hour after the end of surgery, a priming dose of 60 µCi of [3H]inulin (Amersham International, Aylesbury, UK) was given via the femoral vein cannula, followed by an infusion of 60 µCi [3H]inulin/h in isotonic saline (1 ml/h). This infusion replaced the initial saline infusion and was continued for the rest of the experiment.CBX group (corticosterone and CBX; n = 12 rats). Corticosterone, dissolved in isotonic saline containing 2% ethanol, was infused through one of the jugular cannulas (80 µg/ml, 3 ml/h) to administer corticosterone at 240 µg/h. Isotonic saline was infused at 2 ml/h through the right femoral cannula.
One hour after the end of surgery, the saline infusion into the femoral vein was replaced by [3H]inulin in saline (60 µCi primer plus 60 µCi/h at 1 ml/h). At the same time, an infusion of CBX (Sigma; 6 mg/ml) was initiated through the second jugular cannula at a rate of 1 ml/h, making a total fluid infusion rate of 5 ml/h. For both groups of rats, micropuncture collections were begun 1 h after the start of the [3H]inulin infusion. Throughout the micropuncture period (3-4 h), small arterial blood samples were taken for [3H]inulin measurements, and urine collections were made from both micropuncture and contralateral kidneys. Samples of tubule fluid were collected from early and late distal puncture sites by using sharpened glass micropipettes (tip diameter 8-9 µm) filled with mineral oil containing Sudan black dye (39). Identification of distal tubules was made by using intravenous injections of Lissamine green dye (30 µl of 5% solution). These injections were separated by intervals of at least 45 min. For each collection, an oil column of about four to five tubular diameters in length was first injected into the tubule and allowed to flow to a position just downstream of the puncture site. Tubular fluid was then aspirated into the pipette (using initial gentle suction) at a rate that maintained the position of the oil column. At the end of each collection, silicone rubber solution (Microfil; Flow Tech, Carver, MA) was injected into the tubule to allow the subsequent confirmation of the collection site. Collection sites were accepted as "early" if they were in the first third of the distal tubule and as "late" if they were in the final third, the distal tubule being defined as that segment between the macula densa and the confluence with another distal tubule. Micropuncture collections were deposited under water-saturated oil, and their volumes were measured by using calibrated constriction pipettes. Duplicates of each sample were taken for measurement of [3H]inulin; triplicates of each sample were taken for tubular fluid Na+ and K+ measurement. At the end of the experiment, small arterial blood samples were taken for measurement of pH and hematocrit, and a larger sample (~2 ml) was taken for measurement of plasma Na+, K+, osmolality, and (in 3 rats/group) corticosterone. The right kidney was removed, snap-frozen in liquid nitrogen, and stored for subsequent measurement of 11Assessment of the Effect of CBX in the Absence of Corticosterone
In view of a report that high-dose CBX might bind to MR and thus affect electrolyte excretion independently of an action on glucocorticoid metabolism (2), we assessed renal function in two further groups of adrenalectomized animals, prepared in exactly the same way as described above except that neither group received corticosterone. One hour after the end of surgery, both groups received intravenous [3H]inulin (2 µCi primer, 2 µCi/h). At the same time, CBX (6 mg/h) was infused in one group (n = 6 rats), whereas the other group (controls; n = 6 rats) received vehicle alone. Clearance measurements were made during the period 1-4 h after the start of CBX (or vehicle) infusion.11-HSD Assay
Analyses
Arterial blood pressure was measured by using a Druck (Groby, Leicester, UK) pressure transducer. Urinary and plasma Na+ and K+ concentrations were measured by flame photometry (model 543, Instrumentation Laboratory, Warrington, UK). [3H]inulin activities in urine, plasma, and tubular fluid samples were determined by usingPlasma aldosterone was measured by using radioimmunoassay [(14); Coat-A-Count Aldosterone kit, DPC, Los Angeles, CA]. Within-assay coefficients of variation (n = 15) were 6.9 (100-200 pmol/l) and 5.8% (200-400 pmol/l); between-assay coefficients of variation (n = 15) were 7.8 (100-200 pmol/l) and 6.9% (200-400 pmol/l). However, subsequent studies established that the antibody used in the assay cross-reacted with both corticosterone and CBX, thus invalidating the data. Accordingly, we measured plasma aldosterone in a separate group of adrenalectomized, hormone-replaced rats (n = 9) that had been prepared in the same way as the other rats in the present study except that neither corticosterone nor CBX was infused. The plasma aldosterone concentration of these rats was 188 ± 35 pmol/l.
Plasma corticosterone levels were also measured by radioimmunoassay (7). Within- assay and between-assay coefficients of variation were 9.2 (n = 10) and 9.4% (n = 10), respectively.
Calculations
Mean arterial blood pressure was calculated as diastolic pressure plus one-third of the pulse pressure. Glomerular filtration rate (GFR) was calculated as the renal clearance of [3H]inulin. The fractional excretions of Na+ (FENa), K+ (FEK), and water (FEH2O) were calculated as the clearances of Na+ and K+, and urine flow rate, respectively, divided by GFR. Single-nephron GFR (SNGFR) was calculated as TF/PIn multiplied by VTF, where TF/PIn is the tubular fluid/plasma concentration ratio for [3H]inulin and VTF is the tubular fluid flow rate. Fractional deliveries of Na+ and K+ to the distal collection sites were calculated as [(TF/PNa)/(TF/PIn)] × 100 and [(TF/PK)/(TF/PIn)] × 100, respectively, where TF/PNa and TF/PK are the tubular fluid/plasma concentration ratios for Na+ and K+.Statistics
Results are presented as means ± SE. Statistical comparisons between the two groups of rats were made using Student's unpaired t-test. Within-group comparisons (i.e., early distal vs. late distal fractional deliveries) were assessed by using Student's paired t-test. A value of P < 0.05 was considered to be statistically significant. ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effect of CBX in the Presence of Corticosterone
Blood pressure and clearance data.
Mean arterial pressure was not significantly different between the two
groups of rats (103 ± 3 mmHg, corticosterone alone; 108 ± 4 mmHg, corticosterone+CBX). Overall clearance data for the left
(micropunctured) kidney are shown in Fig.
1; values for the right kidney were very
similar. Total GFR was similar in the two groups of animals.
FEH2O was lower in the CBX-treated rats, as was FENa, but FEK was unaffected.
|
Blood and plasma data.
Table 1 shows values from blood samples
taken at the end of each experiment. Arterial pH, plasma osmolality,
and plasma Na+ and K+ concentrations were all
virtually identical in the two groups of rats. Although hematocrit
tended to be lower in the CBX-treated animals (presumably as a
consequence of reduced Na+ and water excretion in the face
of a constant infusion rate), the apparent difference did not achieve
significance.
|
Micropuncture data.
As with total GFR, there was no difference in SNGFR between the two
groups of rats (37 ± 2 nl/min, corticosterone alone; 36 ± 2 nl/min, corticosterone+CBX). Values for tubular fluid flow rate,
TF/PIn, TF/PNa, and TF/PK at the
two puncture sites are shown in Table 2.
Although tubular fluid flow rate in CBX-treated rats was, on average,
slightly lower (and TF/PIn correspondingly higher) at each
site, in neither case was there a significant difference between the
two groups. The TF/P concentration ratio for Na+ was
slightly, but not significantly, reduced at the early distal site in
the CBX-treated rats; values at the late distal site were very similar
in the two groups. However, for K+, the early distal TF/P
concentration ratio was significantly lower in CBX-treated animals,
whereas, in marked contrast, the late distal TF/PK was
significantly elevated.
|
|
|
Enzyme assay.
NAD+-dependent 11-HSD activity (pmol cortisol converted
to cortisone per mg protein per 30 min), as measured ex vivo in the contralateral kidney, was 26 ± 5 pmol · mg
1 · 30 min
1 in the
corticosterone-alone group and 6 ± 2 pmol · mg
1 · 30 min
1 in the
corticosterone+CBX group. Corresponding values for
NADP+-dependent 11
-HSD activity were 49 ± 13 and
5 ± 1 pmol · mg
1 · 30 min
1. Thus CBX at 6 mg/h reduced enzyme activities to
values similar to those seen previously with this dose
(25).
Effect of CBX in the Absence of Corticosterone
Experiments designed to test the possibility that the dose of CBX used might itself have directly influenced renal electrolyte excretion, independently of an effect on corticosterone metabolism, yielded negative findings. In the control group (adrenalectomized, receiving no corticosterone infusion), FENa was 1.9 ± 0.5%; in the CBX-treated animals (adrenalectomized, receiving no corticosterone infusion, CBX infused at 6 mg/h), FENa was 2.3 ± 0.5%. Corresponding values for FEK were 33 ± 4 and 28 ± 2%, respectively. Thus no evidence for a direct mineralocorticoid-like effect was seen with this dose of CBX. ![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Two isoforms of 11-HSD exist within the rat kidney: type 1, found in the proximal tubule (1), the function of which is being examined elsewhere (6), and type 2, found in the
distal nephron (1, 17, 29), which was the focus of the
present investigation.
CBX has been used in a number of previous studies as a means of
inhibiting 11-HSD to test the hypothesis that 11
-HSD2 normally prevents access of glucocorticoids to MR and thus prevents
Na+ retention. Although administration of CBX to humans and
to rats was found to produce the anticipated reduction in
Na+ excretion, in most studies no direct evidence that the
enzyme had been inhibited was provided (18, 30, 34). In a
recent investigation in this laboratory, we administered CBX to
anesthetized rats and measured not only Na+ excretion but
also renal 11
-HSD activities, the latter assessed ex vivo by direct
enzyme assay (25). We found that a dose of CBX sufficient
to reduce 11
-HSD activities by >90% caused a significant lowering
of FENa (although smaller doses, which caused 50-80% enzyme inhibition, had no significant effect on excretion rates, suggesting either that 11
-HSD has considerable functional reserve or
that alternative mechanisms confer MR specificity). In that (clearance)
study, it was not possible to ascertain the site of enhanced
Na+ reabsorption. Moreover, adrenal-intact rats were used,
and plasma aldosterone and corticosterone levels were therefore
uncontrolled. Therefore, we performed the present micropuncture study
in adrenalectomized rats.
The adrenalectomized, hormone-replaced rat model we employed was first
developed by Martin et al. (19) and was subsequently used
by Stanton and colleagues (10, 32) to assess the renal effects of aldosterone and glucocorticoids in the absence of
anesthesia- and surgery-induced fluctuations in endogenous hormone
levels. We found that plasma aldosterone concentrations, measured in
preliminary studies in non-corticosterone-infused rats, were
predictably low and similar to those reported previously in this model
(32, 41). The fact that, before anesthesia, the rats drank
significant quantities of hypertonic saline is further evidence that
the replacement dose of aldosterone was not excessive, because rats
will only drink saline of this strength if they are Na+
deficient (22, 23). Plasma corticosterone concentrations were measured in three rats from each group and ranged from 0.9 to 1.2 µmol/l; these are typical of values found in intact, stressed rats
(C. Kenyon, personal communication). Thus sufficient corticosterone was
present to test the hypothesis of a guardian role for 11-HSD.
The dose of CBX was the same as that previously shown to inhibit renal
11-HSD in intact rats by >90% (25). In the present study, as in the previous one, 11
-HSD activities in CBX-treated rats
were close to zero. The only difference between the two studies was
that baseline values in adrenal-intact rats were greater than those in
adrenalectomized animals. This finding, which conflicts with that of
Alfaidy et al. (1), raises the possibility that enzyme
activity is downregulated when adrenocortical hormones are chronically
depleted. This would be consistent with recent evidence that 11
-HSD
activity is subject to physiological control (21, 36). Of
the two isoforms of 11
-HSD, type 1 can employ either
NAD+ or NADP+ as a cofactor, whereas type 2 has
an absolute requirement for NAD+. The fact that
NAD+- and NADP+-dependent activities were both
suppressed confirms that the CBX had inhibited both isoforms.
As a precaution, in view of an early report that very-high-dose CBX could bind to MR and thereby directly reduce the urinary Na+/K+ ratio (2), in the present study we administered CBX to a group of adrenalectomized rats that was not infused with corticosterone. Under these circumstances, no evidence for a reduction in Na+ excretion or in the urinary Na+/K+ ratio was seen. It is clear, therefore, that the CBX dose employed in our studies (6 mg/h) is insufficient to cause significant direct mineralocorticoid-like actions in vivo.
In contrast, in adrenalectomized rats infused with high-dose
corticosterone, the effect of renal 11-HSD inhibition by this dose
of CBX on overall electrolyte excretion was very similar to that
previously observed in adrenal-intact animals: marked reductions in
absolute Na+ excretion and FENa in the absence
of a change in GFR, and no discernible effect on K+
excretion. The present micropuncture study, in which Na+
and K+ deliveries to the start and end of the distal tubule
were measured directly, is the first investigation into the renal
site(s) of action of CBX. At the early distal tubule, it was found that
CBX treatment caused a significant reduction in K+ delivery
when compared with values in rats infused with corticosterone alone.
(The mean Na+ delivery was also slightly reduced, but the
reduction did not achieve statistical significance.) Although there is
some in vitro evidence that inhibition of proximal tubular 11
-HSD
may affect ion transport in that segment (6), the reduced
early distal K+ delivery we observed was associated with a
significant lowering of the TF/PK, which suggests increased
K+ reabsorption in the loop of Henle rather than in the
proximal tubule; any change in the latter would be expected to affect
solute and water transport similarly. In this context, there is good evidence that aldosterone can stimulate K+ (and, to a much
lesser extent, Na+) reabsorption in the thick ascending
limb of Henle (TALH) (31). Because 11
-HSD activity has
been identified in microdissected segments of cortical TALH (4,
15, 17), it is tempting to speculate that CBX, by inhibiting
11
-HSD in the TALH, was allowing corticosterone to exhibit
mineralocorticoid-like activity in this nephron segment.
Leaving aside its effects in the loop, the major renal sites of action
of aldosterone are generally believed to be the late distal tubule and
cortical collecting tubule (24). However, autoradiographic
studies have revealed aldosterone binding sites throughout the whole of
the distal nephron, from distal convoluted tubule (DCT) to medullary
collecting duct (9). The potential therefore exists for
aldosterone to exert effects within the early, as well as late, distal
tubule, a proposition supported by recent microperfusion evidence
(37). In this context, although most studies of 11-HSD2
distribution have focused on cortical collecting tubule, it is becoming
increasingly apparent that, like MR, the enzyme is present throughout
the whole of the distal nephron (5, 15, 17, 38). If
11
-HSD2 were to fulfill its putative guardian role in the distal
nephron, it might therefore be expected that inhibition of the enzyme
would allow access of corticosterone to MR in all aldosterone-sensitive
segments (including the early distal tubule) and thereby stimulate
Na+ reabsorption and K+ secretion. In the
event, however, the present study was unable to provide any evidence
for enhanced Na+ reabsorption in the accessible distal
tubule of CBX-treated animals. (The distal tubule comprises the DCT,
connecting tubule, and initial collecting tubule. It is likely that our
"early distal" collection site was located within the DCT
and our "late distal" site within the initial collecting tubule.)
At first sight, this negative finding might suggest that the enzyme has
no functional role to play in the distal nephron. However, it should be
remembered that FENa was reduced in CBX-treated animals;
moreover, K+ secretion in the accessible distal tubule was
enhanced (see below). An explanation for the absence of an effect on
distal tubular Na+ reabsorption may be found in the
apparently conflicting findings of previous microperfusion studies of
the action of aldosterone itself on distal tubular function. Stanton
(31) reported that a chronic replacement dose of
aldosterone in adrenalectomized rats restored Na+
reabsorption and K+ secretion to values indistinguishable
from those in intact rats. Similarly, Velazquez and colleagues showed
that chronic high-dose aldosterone could enhance distal tubular
Na+ reabsorption in the adrenalectomized, hormone-replaced
rat model (37). In contrast, the acute infusion of
high-dose aldosterone into adrenalectomized, hormone-replaced rats,
although producing the expected reduction in Na+ excretion,
caused no enhancement of distal tubular Na+ reabsorption
(but nevertheless stimulated K+ secretion)
(10). Thus the time course of aldosterone's action on
Na+ transport within the distal tubule may differ from that
on K+ transport. In the present study, it is possible that
the acute inhibition of 11
-HSD is analogous to the acute infusion of aldosterone.
As already indicated, even though we found end-distal fractional
Na+ deliveries to be identical in the two groups of rats,
FENa was reduced in CBX-treated animals. One possible
explanation for this could be that CBX somehow altered the relative
end-distal Na+ deliveries from (accessible) superficial and
(nonaccessible) juxtamedullary nephrons; i.e., that Na+
reabsorption in juxtamedullary nephrons was enhanced. (Unfortunately, no information is available on the distribution of 11-HSD between superficial and juxtamedullary nephrons.) The alternative, and in our
view more likely, explanation for our findings is that inhibition of
11
-HSD resulted in enhanced reabsorption of Na+ in the
collecting duct.
In the absence of CBX, K+ delivery to the late distal
tubule was not significantly greater than that to the early distal
tubule. Thus the replacement dose of aldosterone employed was
insufficient to stimulate net K+ secretion in the
accessible distal tubule. In contrast, during inhibition of 11-HSD
with CBX, there was clear evidence of K+ secretion: the
fractional delivery of K+ to the late distal site was more
than double that to the early distal tubule, and the late distal
TF/PK was higher than the corresponding value in the
corticosterone-alone group (in the absence of a difference in distal
tubular water reabsorption between the 2 groups). The increase in
distal tubular K+ secretion during CBX treatment occurred
in the absence of an increase in tubular fluid flow rate (which was
actually slightly depressed) or of alterations in arterial pH or plasma
K+, factors known to influence K+ secretion
(12). Stimulation of distal tubular K+
secretion after inhibition of 11
-HSD is consistent with a
mineralocorticoid-like effect of corticosterone, and, to our knowledge,
provides the first in vivo evidence that inhibition of the enzyme leads
to altered distal nephron function.
It may seem surprising, on the basis of present models of principal cell function, that the increase in distal tubular K+ secretion was unaccompanied by an increase in Na+ reabsorption. However, as noted above, there is a precedent for this finding in that acute aldosterone treatment causes a marked increase in distal tubular K+ secretion without a concomitant increase in Na+ reabsorption (10). Moreover, the magnitude of K+ secretion is small (in absolute terms) compared with Na+ reabsorption. In the present study, absolute Na+ reabsorption in the accessible distal tubule was ~300 pmol/min in both groups, whereas the difference in K+ secretion between the two groups amounted to ~10 pmol/min. Thus, even if the stoichiometry of Na+ and K+ transport in the distal tubule were assumed to be fixed, only a small percent change in Na+ reabsorption would be required to account for the change in K+ handling.
The effect of CBX on distal tubular K+ secretion was not accompanied by an increase in urinary K+ excretion, a situation that again mimics that seen during the acute infusion of high-dose aldosterone (10). It is unnecessary to infer from this that K+ must have been reabsorbed in the collecting duct, because the reduced fractional K+ delivery to the early distal tubule meant that, despite enhanced secretion, the fractional delivery to the late distal tubule was not significantly greater than that in rats given corticosterone alone. Nevertheless, if, as argued above, Na+ reabsorption in the collecting duct was increased during CBX treatment, it might be anticipated that K+ secretion would be enhanced in this nephron segment. That no such enhancement occurred could be attributable to a number of factors: 1) urine flow rate was lowered during CBX treatment, and a reduced flow rate through the cortical collecting duct would tend to offset any enhancement of K+ secretion; 2) not all the K+ secreted into the cortical collecting duct completes the journey to the final urine, as some is reabsorbed in the inner stripe of the outer medulla (35); and 3) in the in vitro situation, at least, aldosterone-stimulated Na+ reabsorption by rat inner medullary collecting duct cells occurs in the absence of altered K+ transport (13).
In conclusion, we suggest that the close similarity between the effects
of 11-HSD inhibition, as documented in the present study, and the
effects of intravenous infusion of high-dose aldosterone in the same
rat model (10) provides further evidence that 11
-HSD2 normally acts to protect MR in the distal nephron from the effects of
circulating glucocorticoids.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank the National Kidney Research Fund for financial support, J. Skinner and E. J. Folkerd for technical assistance, A. E. Michael and A. Thompson for enzyme assays, N. Payne for aldosterone measurements, and C. Kenyon for corticosterone measurements. We acknowledge the contribution of our valued colleague and trusted friend, the late Katharine J. Biller.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: D. G. Shirley, Centre for Nephrology, Institute of Urology and Nephrology, Middlesex Hospital, Mortimer St., London W1N 8AA, UK.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 24 September 1999; accepted in final form 31 August 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Alfaidy, N,
Blot-Chabaud M,
Robic D,
Kenouch S,
Bourbouze R,
Bonvalet JP,
and
Farman N.
Characteristics and regulation of 11-hydroxysteroid dehydrogenase of proximal and distal nephron.
Biochim Biophys Acta
1243:
461-468,
1995[ISI][Medline].
2.
Armanini, D,
Karbowiak I,
Krozowski Z,
Funder JW,
and
Adam WR.
The mechanism of mineralocorticoid action of carbenoxolone.
Endocrinology
111:
1683-1686,
1982[Abstract].
3.
Bens, M,
Vallet V,
Cluzeaud F,
Pascual-Letallec L,
Kahn A,
Rafestin-Oblin ME,
Rossier BC,
and
Vandewalle A.
Corticosteroid-dependent sodium transport in a novel immortalized mouse collecting duct principal cell line.
J Am Soc Nephrol
10:
923-934,
1999
4.
Bonvalet, JP,
Doignon I,
Blot-Chabaud M,
Pradelles P,
and
Farman N.
Distribution of 11-hydroxysteroid dehydrogenase along the rabbit nephron.
J Clin Invest
86:
832-837,
1990[ISI][Medline].
5.
Bostanjoglo, M,
Reeves WB,
Reilly RF,
Velazquez H,
Robertson N,
Litwack G,
Morsing P,
Dorup J,
Bachmann S,
and
Ellison DH.
11-Hydroxysteroid dehydrogenase, mineralocorticoid receptor, and thiazide-sensitive Na-Cl cotransporter expression by distal tubules.
J Am Soc Nephrol
9:
1347-1358,
1998[Abstract].
6.
Brem, AS,
Bina RB,
Fitzpatrick C,
King T,
Tang SS,
and
Ingelfinger JR.
Glucocorticoid metabolism in proximal tubules modulates angiotensin II-induced electrolyte transport.
Proc Soc Exp Biol Med
221:
111-117,
1999[Abstract].
7.
Connell, JMC,
Kenyon CJ,
Ball SG,
Davies DL,
and
Fraser R.
Dopamine effects on adrenocorticotrophin-stimulated aldosterone, cortisol, corticosterone and 11-deoxycorticosteroid concentrations in sodium-replete and sodium-deplete man.
J Endocrinol
109:
339-344,
1986[Abstract].
8.
Edwards, CRW,
Stewart PM,
Burt D,
Brett L,
McIntyre MA,
Sutanto WS,
de Kloet ER,
and
Monder C.
Localisation of 11-hydroxysteroid dehydrogenase
tissue specific protector of the mineralocorticoid receptor.
Lancet
ii:
986-989,
1988.
9.
Farman, N,
and
Bonvalet JP.
Aldosterone binding in isolated tubules. III. Autoradiography along the rat nephron.
Am J Physiol Renal Fluid Electrolyte Physiol
245:
F606-F614,
1983[ISI][Medline].
10.
Field, MJ,
Stanton BA,
and
Giebisch GH.
Differential acute effects of aldosterone, dexamethasone, and hyperkalemia on distal tubular potassium secretion in the rat kidney.
J Clin Invest
74:
1792-1802,
1984[ISI][Medline].
11.
Funder, JW,
Pearce PT,
Smith R,
and
Smith AI.
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated.
Science
242:
583-585,
1988[ISI][Medline].
12.
Giebisch, G.
Renal potassium transport: mechanisms and regulation.
Am J Physiol Renal Physiol
274:
F817-F833,
1998
13.
Husted, RF,
Laplace JR,
and
Stokes JB.
Enhancement of electrogenic Na+ transport across rat inner medullary collecting duct by glucocorticoid and by mineralocorticoid hormones.
J Clin Invest
86:
498-506,
1990[ISI][Medline].
14.
James, VHT,
and
Wilson GA.
Determination of aldosterone in biological fluids.
Method Devel Biochem
5:
149-157,
1976.
15.
Kenouch, S,
Coutry N,
Farman N,
and
Bonvalet JP.
Multiple patterns of 11-hydroxysteroid dehydrogenase catalytic activity along the mammalian nephron.
Kidney Int
42:
56-60,
1992[ISI][Medline].
16.
Kotelevtsev, Y,
Brown RW,
Fleming S,
Kenyon C,
Edwards CRW,
Seckl JR,
and
Mullins JJ.
Hypertension in mice lacking 11-hydroxysteroid dehydrogenase type 2.
J Clin Invest
103:
683-689,
1999
17.
Kyossev, Z,
Walker PD,
and
Reeves WB.
Immunolocalization of NAD-dependent 11-hydroxysteroid dehydrogenase in human kidney and colon.
Kidney Int
49:
271-281,
1996[ISI][Medline].
18.
Latif, SA,
Semafuko WEB,
and
Morris DJ.
Effects of carbenoxolone administered acutely to adrenalectomized rats (in vivo) on renal and hepatic handling of corticosterone by 11-hydroxysteroid dehydrogenase.
Steroids
57:
494-501,
1992[ISI][Medline].
19.
Martin, RS,
Jones WJ,
and
Hayslett JP.
Animal model to study the effect of adrenal hormones on epithelial function.
Kidney Int
24:
386-391,
1983[ISI][Medline].
20.
Naray Fejes-Toth, A,
Watlington CO,
and
Fejes-Toth G.
11-Hydroxysteroid dehydrogenase activity in the renal target cells of aldosterone.
Endocrinology
129:
17-21,
1991[Abstract].
21.
Nolan, PJ,
Knepper MA,
and
Packer RK.
Inhibition of IMCD 11-hydroxysteroid dehydrogenase type 2 by low pH and acute acid loading.
J Am Soc Nephrol
8:
530-534,
1997[Abstract].
22.
Olesen, OV.
Influence of the dietary potassium intake on the natriuretic effect of hydrochlorothiazide in rats.
J Pharmacol Exp Ther
220:
178-182,
1982[Abstract].
23.
Richter, CP.
Increased salt appetite in adrenalectomized rats.
Am J Physiol
115:
155-161,
1936.
24.
Rossier, BC,
and
Palmer LG.
Mechanisms of aldosterone action on sodium and potassium transport.
In: The Kidney: Physiology and Pathophysiology (2nd ed.), edited by Seldin DW,
and Giebisch G.. New York: Raven, 1992, p. 1373-1409.
25.
Sewell, KJ,
Shirley DG,
Michael AE,
Thompson A,
Norgate DP,
and
Unwin RJ.
Inhibition of renal 11-hydroxysteroid dehydrogenase in vivo by carbenoxolone in the rat and its relationship to sodium excretion.
Clin Sci (Colch)
95:
435-443,
1998[ISI][Medline].
26.
Sheppard, KE,
and
Funder JW.
Equivalent affinity of aldosterone and corticosterone for type I receptors in kidney and hippocampus: direct binding studies.
J Steroid Biochem
28:
737-742,
1987[ISI][Medline].
27.
Shirley, DG,
Walter SJ,
Folkerd EJ,
Unwin RJ,
and
Bailey MA.
Transepithelial electrochemical gradients in the proximal convoluted tubule during potassium depletion in the rat.
J Physiol (Lond)
513:
551-557,
1998
28.
Shirley, DG,
Zewde T,
and
Walter SJ.
Renal function in normal and potassium-depleted rats before and after preparation for micropuncture experimentation.
Pflügers Arch
416:
74-79,
1990[ISI][Medline].
29.
Smith, RE,
Li KXZ,
Andrews RS,
and
Krozowski Z.
Immunohistochemical and molecular characterization of the rat 11-hydroxysteroid dehydrogenase type II enzyme.
Endocrinology
138:
540-547,
1997
30.
Souness, GW,
and
Morris DJ.
The antinatriuretic and kaliuretic effects of the glucocorticoids corticosterone and cortisol following pretreatment with carbenoxolone sodium (a liquorice derivative) in the adrenalectomized rat.
Endocrinology
124:
1588-1590,
1989[Abstract].
31.
Stanton, BA.
Regulation by adrenal corticosteroids of sodium and potassium transport in loop of Henle and distal tubule of rat kidney.
J Clin Invest
78:
1612-1620,
1986[ISI][Medline].
32.
Stanton, B,
Giebisch G,
Klein-Robbenhaar G,
Wade J,
and
deFronzo RA.
Effects of adrenalectomy and chronic adrenal corticosteroid replacement on potassium transport in rat kidney.
J Clin Invest
75:
1317-1326,
1985[ISI][Medline].
33.
Stewart, PM,
Krozowski ZS,
Gupta A,
Milford DV,
Howie AJ,
Sheppard MC,
and
Whorwood CB.
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11-hydroxysteroid dehydrogenase type 2 gene.
Lancet
347:
88-91,
1996[ISI][Medline].
34.
Stewart, PM,
Wallace AM,
Atherden SM,
Shearing CH,
and
Edwards CRW
Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11-hydroxysteroid dehydrogenase activity in man.
Clin Sci (Colch)
78:
49-54,
1990[ISI][Medline].
35.
Stokes, JB.
Ion transport by the collecting duct.
Semin Nephrol
13:
202-212,
1993[ISI][Medline].
36.
Thompson, A,
Bailey MA,
Michael AE,
and
Unwin RJ.
Effects of changes in dietary intake of sodium and potassium and of metabolic acidosis on 11-hydroxysteroid dehydrogenase activities in rat kidney.
Exp Nephrol
8:
44-51,
2000[ISI][Medline].
37.
Velazquez, H,
Bartiss A,
Bernstein P,
and
Ellison DH.
Adrenal steroids stimulate thiazide-sensitive NaCl transport by rat renal distal tubules.
Am J Physiol Renal Fluid Electrolyte Physiol
270:
F211-F219,
1996
38.
Velazquez, H,
Naray Fejes-Toth A,
Silva T,
Andujar E,
Reilly RF,
Desir GV,
and
Ellison DH.
Rabbit distal convoluted tubule coexpresses NaCl cotransporter and 11-hydroxysteroid dehydrogenase II mRNA.
Kidney Int
54:
464-472,
1998[ISI][Medline].
39.
Walter, SJ,
and
Shirley DG.
The effect of chronic hydrochlorothiazide administration on renal function in the rat.
Clin Sci (Colch)
70:
379-387,
1986[ISI][Medline].
40.
White, PC,
Mune T,
and
Agarwal AK.
11-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.
Endocrinol Rev
18:
135-156,
1997
41.
Work, J,
and
Jamison RL.
Effect of adrenalectomy on transport in the rat medullary thick ascending limb.
J Clin Invest
80:
1160-1164,
1987[ISI][Medline].